Candel appoints Maha Radhakrishnan, M.D., to Board; BLA submission for CAN-2409 on track for Q4 2026

Candel Therapeutics, Inc.

Board expanded from 9 to 10 directors; Radhakrishnan named to Class II, term expiring 2026.
Appointment effective June 4, 2025; she receives option for 28,480 shares vesting over 3 years.
Radhakrishnan previously Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024).
Candel targets Q4 2026 Biologics License Application submission for CAN-2409 in prostate cancer.
She also serves as Executive Partner at Sofinnova Investments since August 2024.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Maha Radhakrishnan, M.D.

Director

CADL · Candel Therapeutics, Inc.

Effective: 2025-06-04
Filed: Jun 06, 2025 23:59 UTC

On June 4, 2025, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) to ten (10) directors and unanimously appointed Maha Radhakrishnan, M.D., to fill the newly created vacancy on the Board, effective June 4, 2025.

Source: SEC EDGAR

accession 0000950170-25-082705

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.